Current treatment of acute myeloid leukemia

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 711-719

  Roboz, Gail J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

acute myeloid leukemia; molecular genomics; treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; AZACITIDINE; BORTEZOMIB; CD135 ANTIGEN; CLOFARABINE; CORE BINDING FACTOR; CYTARABINE; DASATINIB; DAUNORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LENALIDOMIDE; MIDOSTAURIN; MITOXANTRONE; MYLOTRAG; PANOBINOSTAT; PF 04449913; QUIZARTINIB; RETINOIC ACID; SORAFENIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; VORINOSTAT; VOSAROXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; LOW DRUG DOSE; MOLECULAR GENETICS; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; HUMANS; INDIVIDUALIZED MEDICINE; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; STEM CELL TRANSPLANTATION;

EID: 84868196033     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328358f62d     Document Type: Review

References (85)

1. National Cancer Institute. SEER stat fact sheets: acute myeloid leukemia. 2012. http://seer.cancer.gov/statfacts/html/amyl.html. [Accessed 25 July 2012]
2. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010; 28:586-595.
3. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27:61-69.
4. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361:1249-1259.
5. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
6. Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29:4417-4423.
7. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481-3485.
8. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or highrisk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106:1090-1098.
9. Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145:598-605.
10. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010; 115:453-474.
11. Paschka P,Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24:3904-3911.
12. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366:1079-1089.
13. Perrot A, Luquet I, Pigneux A, et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 2011; 118:679-685.
14. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791-4797.
15. Medeiros BC, Othus M, Fang M, et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010; 116:2224-2228.
16. Kayser S, Zucknick M, Dohner K, et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2012; 119:551-558.
17. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-1918.
18. Marcucci G, Haferlach T, Dohner H.Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29:475-486.
19. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute myeloid leukemia [updated 21 December 2010].
20. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111:2776-2784.
21. How J, Sykes J, Gupta V, et al. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer 2012.
22. Schnittger S, Bacher U, Kern W, et al. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011; 25:1297-1304.
23. Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 2012. [Epub ahead of print]
24. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011; 29:1373-1381.
25. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:2348-2355.
26. Green CL, Evans CM, Hills RK, et al. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010; 116:2779-2782.
27. Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118:409-412.
28. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150:264-278.
29. Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485:260-263.
30. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878)
31. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998; 103:100-109.
32. Appelbaum FR, Dahlberg S, Thomas ED, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med 1984; 101:581-588.
33. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833,9621. J Clin Oncol 2004; 22:4290-4301.
34. Castaigne S, Chevret S, Archimbaud E, et al. Randomized comparison of double induction and timed-sequential induction to a '3+7' induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004; 104:2467-2474.
35. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011; 117:2358-2365.
36. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235-1248.
37. ClinicalTrails.gov. Safety and efficacy study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia (IDAML). 2012. http://clinicaltrials.gov/ct2/show/NCT01518556?term= idarubicin+aml+induction&recr=Open&rank=3. [Accessed 28 July 2012]
38. ClinicalTrails.gov. Idarubicin versus high dose daunorubicin in acute myelogenous leukemia (AML) (AIvsAD). 2010. http://clinicaltrials.gov/ct2/show/ NCT01145846?term=idarubicin+and+aml+induction&recr=Open&rank=7. [Accessed 28 July 2012]
39. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of cancer and leukemia group B. Blood 1991; 78:2520-2526.
40. Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 1987; 69:1441-1449.
41. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer 2006; 107:116-124.
42. Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabinebased induction chemotherapy. Blood 2010; 116:5818-5823;
43. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364:1027-1036.
44. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896-903.
45. Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004; 22:1087-1094.
46. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58:4173-4179.
47. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999; 17: 3767-3775.
48. Schaich M, Rollig C, Soucek S, et al. Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 2011; 29:2696-2702.
49. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012; 30:2441-2448.
50. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28:2389-2395.
51. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28:549-555.
52. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112:1638-1645.
53. ClinicalTrials.gov. Clofarabine or daunorubicin hydrochloride and cytarabine followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. 2009. http://clinicaltrials.gov/ct2/ show/NCT01041703?term=clofarabine+daunorubicin+aml&rank=1. [Accessed 28 July 2012]
54. ClinicalTrials.gov. Dose escalation of clofarabine in combination with cytarabine and idarubicin as induction therapy in high risk AML (CIARA). 2012. http://clinicaltrials.gov/ct2/show/NCT01534702?term=clofarabine+aml+ induction&rank=1. [Accessed 28 July 2012]
55. ClinicalTrials.gov. 2012. http://www.clinicaltrials.gov. [Accessed 28 July 2012]
56. ClinicalTrials.gov. Study of elacytarabine versus investigator's choice in patients with late stage acute myeloid leukaemia (AML) (CLAVELA). 2010. http://clinicaltrials.gov/ct2/show/NCT01147939?term=elacytarabine+ aml&rank=1. [Accessed 28 July 2012]
57. Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011; 29:979-985.
58. Lancet JE, Ravandi F, Ricklis RM, et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia 2011; 25:1808-1814.
59. ClinicalTrials.gov. Study of vosaroxin or placebo in combination with cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML) (VALOR) [updated 19 July 2012]. 2010. http://clinicaltrials.gov/ct2/show/ NCT01191801?term=vosaroxin&rank=1. [Accessed 28 July 2012]
60. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-232.
61. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28:562-569.
62. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011; 117:2697-2702.
63. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28:556-561.
64. Thomas XG, Dmoszynska A, Wierzbowska A, et al. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. J Clin Oncol 2011; 29 (Suppl):6504.
65. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107:7473-7478.
66. Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111:2364-2373.
67. Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012; 119:6025-6031.
68. ClinicalTrials.gov. Decitabine with or without bortezomib in treating older patients with acute myeloid leukemia. 2011. http://clinicaltrials.gov/ct2/ show/NCT01420926?term=bortezomib+decitabine&rank=2. [Accessed 9 July 2012]
69. Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 2011; 118:1472-1480.
70. ClinicalTrials.gov. Decitabine, cytarabine, and daunorubicin hydrochloride in treating patients with acute myeloid leukemia. 2012. http://clinicaltrials. gov/ct2/show/NCT01627041?term= decitabine+aml+induction&rank=4. [Accessed 18 July 2012]
71. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. ASH Annu Meet Abstr 2009; 114:790.
72. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379:1508-1516.
73. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29:369-377.
74. Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multitargeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010; 28:4339-4345.
75. Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukaemia. Leukemia 2012. doi: 10.1038/leu.2012.115. [Epub ahead of print]
76. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010; 28:1856-1862.
77. ClinicalTrials.gov. Sorafenib tosylate and chemotherapy in treating older patients with acute myeloid leukemia [updated 16 September 2011]. 2010. http://clinicaltrials.gov/ct2/show/NCT01253070?term=sorafenib+ aml&rank=8. [Accessed 28 July 2012]
78. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113:6567-6571.
79. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114:2984-2992.
80. Raponi M, Lancet JE, Fan H, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008; 111:2589-2596.
81. Schlenk RF, Frohling S, Hartmann F, et al. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment trial. Leukemia 2006; 20:748-750.
82. ClinicalTrials.gov. Zarnestra in newly diagnosed acute myelogenous leukemia (AML) with 2 gene expression signature ratio. 2011. http://clinicaltrials.gov/ct2/show/NCT01361464?term=tipifarnib&rank=16. [Accessed 28 July 2012]
83. ClinicalTrials.gov. Combination chemotherapy and dasatinib in treating patients with newly diagnosed acute myeloid leukemia. 2010. http:// clinicaltrials. gov/ct2/show/NCT01238211?term=dasatinib+aml&rank=3. [Accessed 28 July 2012]
84. ClinicalTrials.gov. Study of dasatinib and all-trans retinoic acid for relapsed/refractory and/or elderly patients with acute myelogenous leukemia (AML). 2009. http://clinicaltrials.gov/ct2/show/NCT00892190?term=dasatinib+ aml&rank=2. [Accessed 28 July 2012]
85. Roboz GJ, Guzman M. Acute myeloid leukemia stem cells: seek and destroy. Expert Rev Hematol 2009; 2:663-672.